Form 4: Director Namandje Bumpus Sells Recursion Pharmaceuticals Stock

Director Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals (RXRX) at $3.54 per share via a Rule 10b5-1 plan.

Summary

• Director Namandje Bumpus disposed of 4,386 shares of Class A Common Stock.
• The transaction occurred on June 3, 2026, at a price of $3.54 per share.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on March 3, 2026.
• Following the transaction, the reporting person retains 43,171 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard practice and does not necessarily reflect a change in the director's outlook on the company.

Positives

• The sale was conducted through a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, often used to provide liquidity for executives and directors while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings to avoid potential insider trading allegations.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

RXRX, Recursion Pharmaceuticals, Insider Trading, Form 4, Namandje Bumpus, Biotech